entertainment -WSS

entertainment

author：hotspot 2025-09-30 23:40:38 - browse：71264

A gene therapy study, halted when four children with a rare neuromuscular disorder died after treatment, showed enough promise to merit finding a path forward, according to the medicine’s manufacturer.

The treatment, made by the Japanese pharmaceutical company Astellas, led to severe and fatal liver problems for four of the 24 treated children with X-linked myotubular myopathy, or XLMTM, a genetic disease that severely degrades muscle function and kills most patients before the age of 10. Three died in 2020; the fourth died a year later.

In an analysis of its clinical trial, published in Lancet Neurology on Wednesday, Astellas observed dramatic benefits in the study’s surviving patients and a potential explanation for the deaths that derailed the trial. The hope, for Astellas and for families affected by XLMTM, is that the company can find a safe way to proceed and convince the Food and Drug Administration to allow it to resume development.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Stanford updates investigation of president’s past research

leisure time

WSS

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Roche's accidental data boosts hopes for anti

'Reaching a detente': STAT's Helen Branswell on covering Covid

Ebola public health emergency is over, WHO declares

Health officials lay out plans to cope with respiratory virus season

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

hotspot

entertainment

explore

Sports medicine is finally prioritizing gender equality

Celebrate National Dole Whip Day for 3 days this week at Disney

Activists slam private health insurers over coverage restrictions

Can U.S. cancer drug shortages be fixed?

Wildfire smoke exposes gaps in outdoor worker protections

Seattle police shoot person suspected in downtown stabbing

BioMarin wins approval for gene therapy to treat hemophilia A

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

Tori Bowie and the unacceptable rates of Black maternal death

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

leisure time

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

Why some people catch Covid but never get sick

Meadows told special counsel he could not recall Trump ever declassifying Mar

Ebola public health emergency is over, WHO declares

knowledge

leisure time

focus

entertainment